Hutrukin to Analyze Safety and PK in Healthy Volunteers

XBiotech

Status and phase: Completed; Phase 1

Conditions: Pharmacokinetics

Treatments: Biological: Placebo; Biological: Hutrukin

Study type: Interventional

Funder types: Industry

Identifiers

NCT05098080

2021-PT054

Details and patient eligibility

About

The study will be a Phase I, open label, safety and pharmacokinetics study of HutrukinTM in at least eight healthy subjects in each of the three dose cohorts (1,000 mg, 3,000 mg and 5,000 mg).

Full description

Study Title: A Randomized Phase I Open-Label, Placebo-Controlled, Dose Escalation Study to Evaluate Safety and Pharmacokinetics of Hutrukin via Intravenous Administration in Healthy Subjects

Sponsor: XBiotech USA, Inc.

Study Chair: Neha Reshamwala, MD

Number of Planned Subjects: 24 healthy subjects with 8 subjects in each of the dose cohorts of HutrukinTM.

Approximate Duration:

Approximately 38 days which includes a screening period of up to 10 days followed by one intravenous push of Hutrukin and then evaluation over 28 days. Blood will be sampled at various time points for blood chemistry, hematological assessment and Hutrukin serum/plasma concentrations. Safety and tolerability will be evaluated.

Enrollment: 24 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Age: ≥18 and weight ≥40 kg.

2. Adequate bone marrow function defined as:

   • absolute neutrophil count (neutrophil and bands) of ≥ 1,500/mm3 (≥ 1.5 x 109/L)
   • platelet count > 150,000/mm3
   • hemoglobin of ≥ 10 g/dL

3. Adequate renal function, defined by serum creatinine ≤ 1.5 x lab ULN.

4. Adequate hepatic function defined as:

   • serum albumin ≥ 3.0 g/dL
   • total bilirubin ≤ 1.5 times lab ULN.
   • alanine aminotransferase (ALT) ≤ 2.0 times lab ULN.
   • aspartate aminotransferase (AST) ≤ 2.0 times lab ULN

5. For female subjects of childbearing potential WOCBP, a negative pregnancy test at screening and the female subjects must agree to either abstain from sexual intercourse or use reliable, effective contraception such as hormonal contraceptive, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, or use of a condom by their partner. Women of non-childbearing potential include those who cannot get pregnant medically, including post-menopausal women and those with a history of hysterectomy or surgical sterilization.

6. Male participants must agree to abstain from sexual intercourse or use a reliable, effective contraceptive method, such as condoms, or have had a vasectomy. Alternatively, female partners of male subjects enrolled in the study must use reliable, effective contraception such as hormonal contraceptive, intrauterine device (IUD), diaphragm with spermicide, or contraceptive sponge.

7. Signed and dated Institutional Review Board (IRB) approved informed consent before any protocol-specific screening procedures are performed.

Exclusion criteria

1. Treatment with any biologicals (including intravenous immunoglobulin) or investigational agents within the last 4 weeks (or 5 half-lives, whichever is longer).

2. Uncontrolled or significant cardiovascular disease, including:

   • A myocardial infarction within the past 6 months.
   • Uncontrolled angina within the past 3 months.
   • Congestive heart failure within the past 3 months, defined as New York Heart Association (NYHA) Class II or higher.
   • Uncontrolled hypertension (blood pressure >160 mm Hg systolic or >100 mm Hg diastolic).

3. Dementia or altered mental status that would prohibit the understanding or rendering of informed consent.

4. Treatment with immunosuppressant agents, including corticosteroids or cyclosporine within the last 4 weeks.

5. History of any clinically significant medical disorders the investigator decides should exclude the participant, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease.

6. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.

7. Abnormal ECG with any clinically significant findings or with QTc >470 ms.

8. Serious infection (example: sepsis, pneumonia, or pyelonephritis), or have been hospitalized or received intravenous (IV) antibiotics for a serious infection during the 3 months prior to the screening visit.

9. Infectious disease:

   • Positive HIV, RPR, Hepatitis B or C, TB (QuantiFERON-TB Gold (QFT)/ IGRA)

10. History of immunodeficiency.

11. Female subjects who are pregnant, planning to become pregnant during the course of the study, or breast-feeding.

12. Major surgery within 28 days prior to Day 0.

13. History of progressive multifocal leukoencephalopathy (PML) or other demyelinating disease.

14. History of malignancy before screening with the exception of squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

24 participants in 2 patient groups, including a placebo group

Hutrukin

Active Comparator group

Description:

At least six healthy subjects in each of the three dose cohorts (1000 mg, 3000 mg, and 5000 mg), will be administered Hutrukin.

Treatment:

Biological: Hutrukin

Placebo

Placebo Comparator group

Description:

At least two healthy subjects in each of the three dose cohorts (1000 mg, 3000 mg, and 5000 mg), will be administered placebo.

Treatment:

Biological: Placebo